ArticleThe British journal of ophthalmology2007
Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.
Article in The British journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review.BMJ open · 2016Pooled it
- The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data.BMC ophthalmology · 2014Pooled it
- [Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2013Pooled it
- Trial
- Trial
- Stepped care for depression and anxiety in visually impaired older adults: multicentre randomised controlled trial.BMJ (Clinical research ed.) · 2015Trial
- [The influence of visual rehabilitation on secondary depressive disorders due to age-related macular degeneration. A randomized controlled pilot study].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2013Trial
- Impact of intravitreal bevacizumab on immune cells in neovascular age related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Health utility values associated with vision impairment among the elderly in Hong Kong: a community-based study using EQ-5D-5 L and time trade-off.Health and quality of life outcomes · 2026Article
- The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review.Health economics review · 2025Review
- Music listening for psychological well-being in adults with acquired vision impairment: a feasibility randomised controlled trial.Frontiers in psychiatry · 2025Article
- Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US.JAMA ophthalmology · 2024Article
- Timely care for age-related macular degeneration: a qualitative study among retina specialists in Israel.Israel journal of health policy research · 2024Article
- Development and Validation of Performance-Based Assessment of Daily Living Tasks in Age-Related Macular Degeneration.Translational vision science & technology · 2024Article
- Prevalence and risk factors for impaired activities of daily living in patients with neo-vascular age-related macular degeneration who present for anti-VEGF treatment.Eye (London, England) · 2024Article
- The role of blood neutrophil lymphocyte ratio in predicting the initial response to anti-VEGF treatment in neovascular AMD patients.Irish journal of medical science · 2024Article
- Advanced Visualization Engineering for Vision Disorders: A Clinically Focused Guide to Current Technology and Future Applications.Annals of biomedical engineering · 2024Review
- Anatomical and Functional Outcomes with Prompt versus Delayed Initiation of Anti-VEGF in Exudative Age-Related Macular Degeneration.Journal of clinical medicine · 2023Article
- Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study.JMIR public health and surveillance · 2023Article
- Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report.The British journal of ophthalmology · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsQuantitative data regarding the impact of neovascular age-related macular degeneration (NV-AMD) on individuals and society is a prerequisite for rational decision-making processes when evaluating alternative treatments for the disease.
methods75 bilateral NV-AMD (patients) and 91 elderly non-AMD (controls) subjects forming the UK cohort of an international cross-sectional, observational study were independently analysed. Subjects completed a telephone survey including the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale (HADS), history of falls and health resource utilisation.
resultsPatients with NV-AMD reported substantially worse vision-related functioning and overall well-being, including higher depression scores, than controls after adjusting for age, gender and co-morbidities (adjusted mean scores: NEI-VFQ-25 overall 52.7 vs 90.7, p<0.0001; EQ-5D 0.67 vs 0.77, p = 0.0273; HADS depression 6.8 vs 4.0, p = 0.0026). Significantly more patients reported a need for assistance with daily activities compared with controls (25.3% vs 6.6%, p = 0.003). Total annual healthcare utilisation costs were more than sevenfold higher for patients with AMD compared with controls ( pound 3,823.89 vs pound 517.05, respectively; p<0.0001)
conclusionsPatients with NV-AMD show a significant decline in quality of life and increased need for daily living assistance compared to a control population without AMD. With the availability of effective new therapies there is a need for improved early access to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.